Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Apr 6;12(1):92-97.
doi: 10.1159/000509850. eCollection 2021 Jan-Apr.

Multimodal Imaging Findings and Treatment with Dexamethasone Implant in Three Cases of Idiopathic Macular Telangiectasia Type 1

Affiliations
Case Reports

Multimodal Imaging Findings and Treatment with Dexamethasone Implant in Three Cases of Idiopathic Macular Telangiectasia Type 1

Paola Cirafici et al. Case Rep Ophthalmol. .

Abstract

This is a report of 3 patients diagnosed with idiopathic macular telangiectasia type 1 (MacTel 1) at Medical Retina Center of the University of Eye Clinic of Genova and then prospectically followed for a mean time of 26 months between 2016 and 2019. It is the first report of patients affected by MacTel 1 treated with dexamethasone (DEX) implant as a first choice of treatment. Aim of our study is to better characterize the disease using a multimodal wide-field imaging and to determine efficacy of DEX implant on MacTel 1 in terms of central macular thickness (CMT) and best-corrected visual acuity (BCVA). MacTel 1 is a rare unilateral disease, characterized by telangiectatic retinal capillaries, cystoid macular edema, and lipid deposition occurring temporal to the fovea. Patients underwent a comprehensive ophthalmic examination, BCVA, swept-source optical coherence tomography (SS-OCT), SS-OCT angiography (SS-OCTA), ultra-widefield (UWF) color, and fluorescein angiography (FA) fundus photograph. All the patients presented monolateral reduced BCVA and macular edema with increased CMT evaluated by SS-OCT. With SS-OCTA, we showed that the telangiectasia-associated vascular changes originate in the deep retinal vascular plexus and as a consequence macular edema and exudation develop causing vision loss. Furthermore, UWF imaging helped us to highlight vascular changes typical of Coats Disease at the far retinal periphery. All the patients were treated with DEX intravitreal implant, showing a decrease in CMT and a stabilization of visual acuity. Due to the recurrent nature of macular edema, patients underwent a mean of 4 DEX implants during the follow-up period. In order to address the clinical features of this uncommon disease avoiding diagnostic errors, it might be important to use a multimodal imaging approach. The anatomical and functional beneficial effects of DEX implant were well evident although transient.

Keywords: Dexamethasone implant; Imaging; MacTel 1; Macular edema; Retina.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Case 2 a. Fundus examinations of the affected showed small hemorrhages, microaneurysms, and lipid exudates located temporal to the fovea. b Early phase FA revealed hyperfluorescent saccular dilatations which exhibited profuse leakage during intermediate (c) and late phase (d). e Swept-source OCT showed increased central retinal thickness and intraretinal cysts. Swept-source OCT angiography showed a mild reduction in the capillary network density of the superficial retinal layer (f), as well as multiple telangiectatic dilated vessels in the deep retinal layers (g) in which it was possible to detect blood flow at structural OCT (h, arrow). FA, fluorescein angiography.
Fig. 2
Fig. 2
Dilated and dropout retinal capillaries in peripheral retinal visible through UWF fundus FA. Case 2 (a, b); Case 3 (c, d). UWF, ultra-widefield; FA, fluorescein angiography.
Fig. 3
Fig. 3
Change in CMT after intravitreal injections of DEX implant in 3 cases of MacTel 1. Case 1 in column (a); Case 2 in column (b); Case 3 in column (c). CMT, central macular thickness.

Similar articles

Cited by

References

    1. Yannuzzi LA, Bardal AM, Freund KB, Chen KJ, Eandi CM, Blodi B. Idiopathic macular telangiectasia. Arch Ophthalmol. 2006 Apr;124((4)):450–60. - PubMed
    1. Nowilaty SR, Al-Shamsi HN, Al-Khars W. Idiopathic juxtafoveolar retinal telangiectasis: a current review. Middle East Afr J Ophthalmol. 2010 Jul;17((3)):224–41. - PMC - PubMed
    1. Pappuru RR, Peguda HK, Dave VP. Optical coherence tomographic angiography in type 1 idiopathic macular telangiectasia. Clin Exp Optom. 2018 Jan;101((1)):143–4. - PubMed
    1. Chatziralli IP, Sharma PK, Sivaprasad S. Treatment Modalities for Idiopathic Macular Telangiectasia: An Evidence-Based Systematic Review of the Literature. Semin Ophthalmol. 2017;32((3)):384–94. - PubMed
    1. Osaka R, Shiragami C, Ono A, Kobayashi M, Takasago Y, Yamashita A, et al. Clinical features of treated and untreated type 1 idiopathic macular telangiectasia without the occurrence of secondary choroidal neovascularization followed for 2 years in japanese patients. Retina. 2018 Jan;38(Suppl 1):S114–22. - PMC - PubMed

Publication types

LinkOut - more resources